Literature DB >> 8226142

Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication.

D E Dosoretz1, D Galmarini, J H Rubenstein, M J Katin, P H Blitzer, S A Salenius, R A Dosani, M Rashid, G Mestas, S E Hannan.   

Abstract

PURPOSE: For patients who are medically unable to tolerate a surgical resection for technically resectable non-small-cell lung carcinoma, radiation therapy is an acceptable alternative. We report on the effect of achieving local control of the primary tumor on survival end-points, and analyze factors that may influence local control. METHODS AND MATERIALS: We reviewed the records of 152 patients with medically inoperable non-small-cell lung carcinoma treated at our institutions. All patients had technically resectable lesions and no evidence of metastatic disease. Treatment was delivered using megavoltage irradiation to doses ranging from 45 to 75 Gy.
RESULTS: For patients with tumors 3 cm or less, locally controlling the tumor significantly improved survival (p = .0371). Patients with T1 tumors had a higher probability of survival and disease-free-survival than patients with larger tumors if the primary tumor was locally controlled, but this survival advantage disappeared if the tumor was not controlled. Overall, patients with smaller tumors had a lower incidence of distant spread, but this association was maintained only when the primary tumor was controlled (36 month risk of 10%, 23%, and 57% for tumors < 3 cm, 3-4.9 cm, 5 cm or greater, respectively, p = .0027). For patients whose tumors were not controlled, there was no significant difference in the risk of distant dissemination by tumor size. Higher radiation doses influenced local control and metastatic spread. We observed no influence of the initial field size in the risk of local control and in the probability of survival.
CONCLUSION: Radical radiation therapy is an effective treatment for small (T1 or < 3 cm) tumors when treated to doses of 65 Gy or more, and should be offered as an alternative to surgery in elderly or infirm patients. New therapeutic strategies to improve the local control rate should be considered for larger tumors, through the use of hyperfractionated treatment, endobronchial "boost" irradiation, and sensitizing chemotherapy agents.

Entities:  

Mesh:

Year:  1993        PMID: 8226142     DOI: 10.1016/0360-3016(93)90373-4

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  13 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

Review 2.  Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review.

Authors:  N P Rowell; C J Williams
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

3.  Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.

Authors:  Joe Y Chang; Ritsuko Komaki; Hong Y Wen; Beth De Gracia; Jaques B Bluett; Mary F McAleer; Stephen G Swisher; Michael Gillin; Radhe Mohan; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-20       Impact factor: 7.038

4.  Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer.

Authors:  Yuhchyau Chen; Kishan J Pandya; Richard Feins; David W Johnstone; Thomas Watson; Therese Smudzin; Peter C Keng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

5.  Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer.

Authors:  Ying Xiao; Lech Papiez; Rebecca Paulus; Robert Timmerman; William L Straube; Walter R Bosch; Jeff Michalski; James M Galvin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038

6.  Low and medium doses of hypofractionated stereotactic radiotherapy could be suboptimal for early-stage lung cancer.

Authors:  Ernesto Maranzano; Lorena Draghini; Romina Rossi; Michelina Casale; Fabio Trippa
Journal:  J Radiosurg SBRT       Date:  2013

7.  Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study.

Authors:  H J Groen; A H van der Leest; E G de Vries; D R Uges; B G Szabó; N H Mulder
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

8.  Dosimetric comparison of helical tomotherapy and conventional Linac-based X-knife stereotactic body radiation therapy for primary lung cancer or pulmonary metastases.

Authors:  Shuangshuang Li; Ju Yang; Juan Liu; Shanbao Gao; Baorui Liu; Jing Yan
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

9.  Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team.

Authors:  Shervin M Shirvani; Joe Y Chang
Journal:  Cancers (Basel)       Date:  2011-09-01       Impact factor: 6.639

10.  High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer.

Authors:  Sun Hyun Bae; Yong Chan Ahn; Heerim Nam; Hee Chul Park; Hong Ryull Pyo; Young Mog Shim; Jhingook Kim; Kwhanmien Kim; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  Yonsei Med J       Date:  2012-11-01       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.